AI Article Synopsis
Article Abstract
Hypertriglyceridemia is a cardiovascular risk factor independent of LDL cholesterol. Omega-3 reduce triglycerides levels, but without proven benefit to reduce cardiovascular risk. Recently, two studies on high-dose omega-3 derivatives have shown contradictory results on the risk of cardiovascular events: REDUCE-IT (4 g/day of icosapent ethyl) showed a 25 % reduction; STRENGTH (4 g/day of a mixture of eicosapentaenoic acid and docosahexaenoic acid) showed no effect. An increased risk of atrial fibrillation was observed in both studies. The European 2021 cardiovascular prevention guidelines propose to consider high-dose ethyl icosapent on a case-by-case basis in patients with hypertriglyceridemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.53738/REVMED.2022.18.772.434 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acceptability of multi-level sexual health interventions and sexually transmitted infection screening and testing among persons with HIV across three clinical sites in Florida.
J Acquir Immune Defic Syndr
November 2024
Division of Infectious Diseases and Global Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Introduction: The US state of Florida has the third highest rate of HIV as well as high rates of sexually transmitted infections (STIs) indicating critical HIV and STI prevention needs remain unmet. To address gaps in the STI care continuum in people with HIV (PWH), evidence-based interventions were implemented across three Ryan White HIV/AIDS Program (RWHAP) funded clinics in Florida between August 2020-August 2021. Interventions included comprehensive sexual health history (SHH) taking using audio computer-assisted self-interview (ACASI) software, self-collected extragenital gonorrhea and chlamydia testing, and the introduction of a lesbian, gay, bisexual, transgender, and queer (LGBTQ+) welcoming environment.
View Article and Find Full Text PDFThe impact of reduced skeletal muscle mass at stroke onset on 3-month functional outcomes in acute ischemic stroke patients.
PLoS One
January 2025
Department of Neurology, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.
Introduction: Sarcopenia, characterized by reduced skeletal muscle mass (RMM), is increasingly recognized as a significant factor influencing outcomes in various health conditions, including stroke. Although most studies focus on sarcopenia developing during stroke rehabilitation, the impact of sarcopenia present at the onset of acute ischemic stroke remains underexplored. This study aims to evaluate the effect of RMM at stroke onset on 3-month functional outcomes in acute ischemic stroke patients.
View Article and Find Full Text PDFRisk Stratification for Cardiovascular Disease: A Comparative Analysis of Cluster Analysis and Traditional Prediction Models.
Eur J Prev Cardiol
January 2025
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Aim: Primary prevention of cardiovascular disease (CVD) relies on effective risk stratification to guide interventions. Current models, primarily developed using regression analysis, can lead to inaccurate estimates when applied to external populations. This study evaluates the utility of cluster analysis as an alternative method for developing CVD risk stratification models, comparing its performance with established CVD risk prediction models.
View Article and Find Full Text PDFStrategies to Optimise the Engagement of Culturally and Linguistically Diverse Populations in Cardiac Research: A Systematic Review.
Eur J Cardiovasc Nurs
January 2025
School of Rural Health, Monash University, Warragul, Victoria, Australia.
Aims: Culturally and linguistically diverse (CALD) populations remain underrepresented in cardiovascular disease (CVD) research despite their higher disease burden compared to non-CALD populations. The purpose of this review is to synthesize the available literature on strategies to engage CALD participants in CVD research.
Methods And Results: Four electronic databases (MEDLINE, EMBASE, CINAHL and PsycINFO) were searched for literature up until May 2024.
GLP-1 and the Neurobiology of Eating Control: Recent Advances.
Endocrinology
January 2025
Centre for Cardiovascular and Metabolic Neuroscience; Dept of Neuroscience, Physiology and Pharmacology; University College London; UK.
Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with bodyweight, affecting more than 1 billion people worldwide. Excess body fat is strongly associated with excess energy intake, and most successful anti-obesity medications (AOMs) counter this positive energy balance through the suppression of eating to drive weight loss. Historically, AOMs have been characterised by modest weight loss and side effects which are compliance-limiting, and in some cases life-threatening.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!